Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: MAP3K2

Summary for MAP3K2

Gene information	Gene symbol	MAP3K2
	Ensembl ID	ENSG00000169967
	Entrez ID	10746
	Gene name	mitogen-activated protein kinase kinase kinase 2
	Synonyms	MEKK2\|MEKK2B
	Gene type	protein_coding
	UniProtAcc	Q9Y2U5

Top

Dataset with differentially expressed gene: MAP3K2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.461038	1.61e-39
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.298647	9.87e-03
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	-0.277969	9.49e-30
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.280528	6.53e-30
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.964014	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.364747	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.270553	0.00e+00
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.252644	9.45e-09
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.372661	0.00e+00

Top

Expression of MAP3K2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to MAP3K2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating MAP3K2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
MAP3K2	hsa-miR-3976	90.9694	NM_006609
MAP3K2	hsa-miR-664a-3p	90.9426	NM_006609
MAP3K2	hsa-miR-19a-3p	90.7885	NM_006609
MAP3K2	hsa-miR-19b-3p	90.7885	NM_006609
MAP3K2	hsa-miR-4275	90.7372	NM_006609
MAP3K2	hsa-miR-7110-3p	90.6877	NM_006609
MAP3K2	hsa-miR-3065-5p	90.3658	NM_006609
MAP3K2	hsa-miR-5692a	90.3523	NM_006609
MAP3K2	hsa-miR-2909	90.3073	NM_006609
MAP3K2	hsa-miR-6719-3p	90.1884	NM_006609
MAP3K2	hsa-miR-5582-5p	90.1881	NM_006609
MAP3K2	hsa-miR-944	90.1612	NM_006609
MAP3K2	hsa-miR-5584-3p	90.0427	NM_006609
MAP3K2	hsa-miR-369-3p	89.9459	NM_006609
MAP3K2	hsa-miR-6739-3p	89.5884	NM_006609
MAP3K2	hsa-miR-130a-5p	89.4057	NM_006609
MAP3K2	hsa-miR-548ah-5p	89.3487	NM_006609
MAP3K2	hsa-miR-3609	89.3487	NM_006609
MAP3K2	hsa-miR-3140-3p	89.2733	NM_006609
MAP3K2	hsa-miR-766-3p	89.2007	NM_006609
MAP3K2	hsa-miR-5582-3p	89.0911	NM_006609
MAP3K2	hsa-miR-6831-5p	88.6705	NM_006609
MAP3K2	hsa-miR-548ar-3p	88.6232	NM_006609
MAP3K2	hsa-miR-4729	87.9683	NM_006609
MAP3K2	hsa-miR-7856-5p	87.8901	NM_006609
MAP3K2	hsa-miR-141-3p	87.6371	NM_006609
MAP3K2	hsa-miR-200a-3p	87.6371	NM_006609
MAP3K2	hsa-miR-4668-5p	87.3911	NM_006609
MAP3K2	hsa-miR-5683	87.1267	NM_006609
MAP3K2	hsa-miR-12123	87.1222	NM_006609
MAP3K2	hsa-miR-218-5p	87.0392	NM_006609
MAP3K2	hsa-miR-1250-3p	86.9393	NM_006609
MAP3K2	hsa-miR-4495	86.8615	NM_006609
MAP3K2	hsa-miR-5680	86.8363	NM_006609
MAP3K2	hsa-miR-4698	86.7904	NM_006609
MAP3K2	hsa-miR-6892-5p	86.7515	NM_006609
MAP3K2	hsa-miR-4511	86.6813	NM_006609
MAP3K2	hsa-miR-493-5p	86.6434	NM_006609
MAP3K2	hsa-miR-3927-3p	86.5029	NM_006609
MAP3K2	hsa-miR-12129	86.4445	NM_006609
MAP3K2	hsa-miR-642a-5p	86.1923	NM_006609
MAP3K2	hsa-miR-3910	86.0993	NM_006609
MAP3K2	hsa-miR-5003-3p	86.0886	NM_006609
MAP3K2	hsa-miR-590-3p	85.9671	NM_006609
MAP3K2	hsa-miR-548b-3p	85.9543	NM_006609
MAP3K2	hsa-miR-1271-5p	85.8947	NM_006609
MAP3K2	hsa-miR-6800-3p	85.6195	NM_006609
MAP3K2	hsa-miR-4326	85.5749	NM_006609
MAP3K2	hsa-miR-4477b	85.5389	NM_006609
MAP3K2	hsa-miR-302c-5p	85.4147	NM_006609

Page: 1 2 3 4 5

Top

Motifs and transcription factors (TFs) regulating MAP3K2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
MAP3K2	transfac_pro__M02865	GMEB1 (inferredBy_Orthology).
MAP3K2	swissregulon__hs__GLIS2	GLIS2 (directAnnotation).
MAP3K2	nitta__CG18619_TCGAAG20NGA_KH_RTGACGTCAT_m1_c3u	CREBL2 (inferredBy_Orthology).
MAP3K2	transfac_public__M00039	CREB1 (directAnnotation).
MAP3K2	tfdimers__MD00411	ELF5; YY1 (directAnnotation).

Page: 1

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
MAP3K2	"Bosutinib"	DB06616	small molecule
MAP3K2	"Fostamatinib"	DB12010	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."